Science and Technology Science and Technology
Wed, March 21, 2012
Tue, March 20, 2012

NicOx's web conference on March 21 - NicOx enters into option agreement to acquire Altacor as a first step towards building an


Published on 2012-03-21 01:21:06 - Market Wire
  Print publication without navigation


March 21, 2012 02:58 ET

NicOx's web conference on March 21 - NicOx enters into option agreement to acquire Altacor as a first step towards building an international ophthalmology business

SOPHIA ANTIPOLIS CEDEX, FRANCE--(Marketwire - Mar 21, 2012) -


ALERT

NicOx's web conference on March 21

NicOx enters into option agreement to acquire Altacor as a first step towards building an international ophthalmology business

TO:

Investors, Analysts and Journalists

WHAT:

NicOx S.A. will hold a web conference today at 11:00 am CET.

SPEAKERS:

Michele Garufi, Chairman and Chief Executive Officer

Eric Castaldi, Chief Financial Officer

Gavin Spencer, VP Business Development

WHEN:

Wednesday March 21, 2012, at 11:00 am CET (10:00 am UK - 6:00 am EST)

Phone number:

+44 (0)20 3140 82 86 or +1 646 254 3362 (for audio and Q&A session)

Conference ID number: 4182419

Access to the web conference available 10 minutes before its start

Web presentation, also downloadable in pdf format, available on NicOx's website: [ www.nicox.com ]

A replay of the web conference will be available from March 22 in the morning until March 28 midnight.

Please confirm your participation to Irène Lalande, Investor and Media Relations Coordinator

Tel: +33 (0)4 97 24 53 11 / [ lalande@nicox.com ]

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a pharmaceutical company focused on the research, development and future commercialization of drug candidates. NicOx is applying its proprietary nitric oxide-donating R&D platform to develop an internal portfolio of New Molecular Entities (NMEs) for the potential treatment of inflammatory, cardio-metabolic and ophthalmological diseases. The Company's pipeline includes several nitric oxide-donating NMEs, which are in development internally and with partners, who include Merck (known as MSD outside the United States and Canada), Bausch + Lomb, and Ferrer.

NicOx S.A. is headquartered in France and is listed on Euronext Paris (Compartment C: Small Caps).

Risks factors which are likely to have a material effect on NicOx's business are presented in the 4(th) chapter of the « Document de référence, rapport financier annuel et rapport de gestion 2011» filed with the French Autorité des Marchés Financiers (AMF) on February 29, 2012 and available on NicOx's website ([ www.nicox.com ]) and on the AMF's website ([ www.amf-france.org ]).

NicOx's web conference on March 21 : [ http://hugin.info/143509/R/1595997/502697.pdf ]

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: NICOX via Thomson Reuters ONE [HUG#1595997]


Contributing Sources